

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
10 January 2019 (10.01.2019)



(10) International Publication Number
WO 2019/008025 A1

(51) International Patent Classification:

<i>C07D 401/14</i> (2006.01)	<i>C07D 451/14</i> (2006.01)
<i>A61K 31/64</i> (2006.01)	<i>C07D 205/04</i> (2006.01)
<i>C07D 217/22</i> (2006.01)	<i>C07D 205/12</i> (2006.01)
<i>C07D 223/06</i> (2006.01)	<i>C07D 207/12</i> (2006.01)
<i>C07D 401/04</i> (2006.01)	<i>C07D 211/54</i> (2006.01)
<i>C07D 401/06</i> (2006.01)	<i>A61P 37/00</i> (2006.01)
<i>C07D 401/12</i> (2006.01)	<i>A61P 9/00</i> (2006.01)
<i>C07D 403/04</i> (2006.01)	<i>A61P 17/00</i> (2006.01)
<i>C07D 403/06</i> (2006.01)	<i>A61P 35/00</i> (2006.01)
<i>C07D 405/04</i> (2006.01)	<i>A61P 31/00</i> (2006.01)
<i>C07D 405/06</i> (2006.01)	<i>A61P 13/12</i> (2006.01)
<i>C07D 409/04</i> (2006.01)	<i>A61P 1/00</i> (2006.01)
<i>C07D 239/66</i> (2006.01)	<i>A61P 11/00</i> (2006.01)
<i>C07D 241/18</i> (2006.01)	<i>A61P 15/00</i> (2006.01)
<i>C07D 451/02</i> (2006.01)	<i>A61P 25/00</i> (2006.01)

(21) International Application Number:

PCT/EP2018/068077

(22) International Filing Date:

04 July 2018 (04.07.2018)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

1710943.0	07 July 2017 (07.07.2017)	GB
1713079.0	15 August 2017 (15.08.2017)	GB
1713082.4	15 August 2017 (15.08.2017)	GB
1718561.2	09 November 2017 (09.11.2017)	GB
1718563.8	09 November 2017 (09.11.2017)	GB
1721726.6	22 December 2017 (22.12.2017)	GB

(71) Applicant: **INFLAZOME LIMITED** [IE/IE]; 88 Harcourt Street, Dublin 2 (IE).

(72) Inventors: **COOPER, Matthew**; c/o Inflazome UK Limited, D6 Grain House, Mill Court, Great Shelford, Cambridge CB22 5LD (GB). **MILLER, David**; c/o Inflazome UK Limited, D6 Grain House, Mill Court, Great Shelford, Cambridge CB22 5LD (GB). **MACLEOD, Angus**; c/o Inflazome UK Limited, D6 Grain House, Mill Court, Great Shelford, Cambridge CB22 5LD (GB). **VAN WILTENBURG, Jimmy**; c/o Syncom B.V., Kadijk 3, 9747 AT Groningen (NL). **THOM, Stephen**; c/o Sygnature Discovery Limited, The Discovery Building BioCity, Penny-

foot Street, Nottingham NG1 1GR (GB). **ST-GALLAY, Stephen**; c/o Sygnature Discovery Limited, The Discovery Building BioCity, Pennyfoot Street, Nottingham NG1 1GR (GB). **SHANNON, Jonathan**; c/o Sygnature Discovery Limited, The Discovery Building BioCity, Pennyfoot Street, Nottingham NG1 1GR (GB).

(74) Agent: **ELEND, Almut** et al.; Venner Shipley LLP, Byron House, Cambridge Business Park, Cowley Road, Cambridge cambridgeshire CB4 0WZ (GB).


(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS



(57) Abstract: The present invention relates to compounds of formula (I) wherein Q is selected from O or S; R¹ is a non-aromatic heterocyclic group comprising at least one ring nitrogen atom, wherein R¹ is attached to the sulfur atom of the sulfonylurea group by a ring carbon atom, and wherein R¹ may optionally be substituted; and R² is a cyclic group substituted at the α -position, wherein R² may optionally be further substituted. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP₃.

WO 2019/008025 A1